Oppenheimer Continues to Expect Sarepta (SRPT) Eteplirsen Approval in the Next Few Months
Tweet Send to a Friend
Oppenheimer analyst Michelle Gilson reiterated an Outperform rating and $60 price target on Sarepta Therapeutic (NASDAQ: SRPT) following results ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
